# Nivestim™ in Treatment of Malignant Diseases

> **NCT01627990** · — · COMPLETED · sponsor: **Hospira, now a wholly owned subsidiary of Pfizer** · enrollment: 386 (actual)

## Conditions studied

- Solid Tumour
- Malignant Haematological Tumour
- Primary or Secondary Prophylactic Treatment

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01627990
- **Lead sponsor:** Hospira, now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 386 (ACTUAL)
- **Last updated:** 2015-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01627990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01627990, "Nivestim™ in Treatment of Malignant Diseases". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01627990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*